Dobrek Lukasz
Department of Clinical Pharmacology, Wroclaw Medical University, Wroclaw, Poland.
Life (Basel). 2023 Jan 24;13(2):325. doi: 10.3390/life13020325.
The overriding goal of the treatment of patients is its effectiveness and safety. However, all medications currently being used also exert some adverse pharmaceutical reactions, which may be regarded as an unintended but inevitable cost of pharmacotherapy. The kidney, as the main organ that eliminates xenobiotics, is an organ especially predisposed and vulnerable to the toxic effects of drugs and their metabolites during their excretion from the body. Moreover, some drugs (e.g., aminoglycosides, cyclosporin A, cisplatin, amphotericin B, and others) have a "preferential" nephrotoxicity potential, and their use is associated with an increased risk of kidney damage. Drug nephrotoxicity is, therefore, both a significant problem and a complication of pharmacotherapy. It should be noted that, currently, there is no generally recognized definition of drug-induced nephrotoxicity and no clear criteria for its diagnosis. This review briefly describes the epidemiology and diagnosis of drug-induced nephrotoxicity and characterizes its pathomechanisms, including immunological and inflammatory disturbances, altered kidney blood flow, tubulointerstitial injury, increased lithogenesis-crystal nephropathy, rhabdomyolysis, and thrombotic microangiopathy. The study also lists the basic drugs with nephrotoxicity potential and provides a short overview of the preventive methods for reducing the risk of drug-related kidney damage developing.
治疗患者的首要目标是疗效和安全性。然而,目前正在使用的所有药物也会产生一些药物不良反应,这可被视为药物治疗中意外但不可避免的代价。肾脏作为清除外源性物质的主要器官,在药物及其代谢产物从体内排泄过程中,特别容易受到药物及其代谢产物毒性作用的影响,且较为脆弱。此外,一些药物(如氨基糖苷类、环孢素A、顺铂、两性霉素B等)具有“优先”的肾毒性潜力,其使用与肾脏损伤风险增加有关。因此,药物肾毒性既是一个重大问题,也是药物治疗的一种并发症。应当指出,目前对于药物性肾毒性尚无普遍认可的定义,也没有明确的诊断标准。本综述简要描述了药物性肾毒性的流行病学和诊断,并阐述了其发病机制,包括免疫和炎症紊乱、肾血流量改变、肾小管间质损伤、结石形成增加——结晶性肾病、横纹肌溶解和血栓性微血管病。该研究还列出了具有肾毒性潜力的基本药物,并简要概述了降低药物相关肾损伤发生风险的预防方法。